RELEASE DATE: December 13, 2019
EXPIRATION DATE: December 13, 2020
This activity was recorded during a supplemental CME/CE symposium at the 2019 National Lipid Association Spring Clinical Lipid Update in Portland just three months after the release of the cardiovascular outcomes trial REDUCE-IT results. Our expert faculty discuss the effects of EPA and provide our learners with insights into the future of management of patients with residual risk for atherosclerotic cardiovascular disease.
Internet Enduring Activity
This activity is designed to meet the needs of lipid specialists, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and those with an interest in lipid management.
At the Conclusion of this activity, participants should be able to:
- Explain EPA’s effects on HDL functionality and cholesterol transport.
- Demonstrate the effect of EPA on atherosclerotic plaque as seen in use of imaging modalities.
- Outline EPA’s pleiotropic effects.
- Apply data from the REDUCE-IT trial into management of patients with residual risk for cardiovascular disease.
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 75% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is December 13, 2020.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
This activity is supported by educational funding provided by Amarin Pharma Inc.
CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this internet enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
Pharmacist Accreditation Statement
Universal Activity Number – JA0007192-0000-19-019-H01-P (Knowledge) This Activity has been approved for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this CE activity is 2.0 contact hours.
For the advanced practice nurse, this activity has 0.3 contact hours of pharmacotherapy content.
John R. Nelson MD, FACC, FNLA, FASNC
Director, California Cardiovascular Institute
Past President-Pacific Lipid Association
ACC-CA Governmental Relations Committee-member
President, National Lipid Association
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Intermountain Medical Center
Director, Lipid Biophysics Laboratory
Brigham & Women’s Hospital
Harvard Medical School
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
|Brown, Alan||Advisory Board
|Akcea, Amgen, Kowa, Regeneron, Sanofi|
|Le, Viet||N/A||Nothing to disclose.|
|Amarin, Amgen, ARCA Bio, Daiichi Sankyo, Pfizer|
|Nelson, John||Advisory Board
|Amarin, Amgen, Boehringer Ingelheim, Boston Heart Diagnostics, Kowa, Regeneron|
|NLA||N/A||NLA staff has nothing to disclose.|
|Bottenberg, B||N/A||Nothing to disclose.|
This page was last updated: Dec 17, 2019